lung cancer

April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

By Leigh MacMillan
December 16, 2021

AI used to identify patients at risk for lung cancer

By Matt Batcheldor
September 23, 2021

Clinical trial tests ATR inhibitor in difficult-to-treat cancers

By Doug Campbell
June 23, 2021

Study shows benefit of scheduling lung screens with mammograms

Women who are longtime smokers could potentially save their lives by undergoing lung screens on the same day they schedule mammograms, according to a study by Vanderbilt researchers published in the Journal of Medical Screening.

By Tom Wilemon
March 18, 2021

Vanderbilt research played key role in new lung screen guidelines

The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.

By Tom Wilemon
March 18, 2021

EGFR Resisters/LUNGevity fund lung cancer research

Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.

By Tom Wilemon
March 9, 2021

Study incorporates genetics with smoking history to identify high-risk smokers for lung cancer screening

A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.
By Tom Wilemon
February 25, 2021

Gift in memory of Phran Galante boosts lung cancer research

A gift in memory of music industry executive and community philanthropist Phran Galante will support the work of Christine Lovly, MD, PhD, associate professor of Medicine and Ingram Professor of Cancer Research, to improve targeted therapies for lung cancer.
By Tom Wilemon
November 12, 2020

New therapeutic target for lung cancer

Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.
By Sarah E. Glass
August 13, 2020

Newer targeted therapy prolongs life for lung cancer patients

Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase 3 study.
By Tom Wilemon
July 30, 2020

Iams honored by National Comprehensive Cancer Network

Wade Iams, MD, MSCI, assistant professor of Medicine, is the recipient of a National Comprehensive Cancer Network Foundation Young Investigator Award.
By Tom Wilemon
July 23, 2020

Criteria for lung cancer screens may be expanded

The U.S. Preventive Services Task Force (USPSTF) is recommending two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
By Tom Wilemon
May 26, 2020

ASCO press program highlights COVID-19 outcomes in lung cancer patients

People with thoracic cancers sickened by COVID-19 were especially vulnerable to deaths with a 35% mortality rate, according to early results from TERAVOLT, a global consortium that tracks outcomes among this vulnerable patient population.
By Tom Wilemon
1 2 3 4 … 8